Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy

Junjian Wang, Haibin Wang, Ling Yu Wang, Demin Cai, Zhijian Duan, Yanhong Zhang, Peng Chen, June X. Zou, Jianzhen Xu, Xinbin Chen, Hsing Jien Kung, Hong Wu Chen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recombinant TRAIL and agonistic antibodies to death receptors (DRs) have been in clinical trial but displayed limited anti-cancer efficacy. Lack of functional DR expression in tumors is a major limiting factor. We report here that chromatin regulator KDM4A/JMJD2A, not KDM4B, has a pivotal role in silencing tumor cell expression of both TRAIL and its receptor DR5. In TRAIL-sensitive and -resistant cancer cells of lung, breast and prostate, KDM4A small-molecule inhibitor compound-4 (C-4) or gene silencing strongly induces TRAIL and DR5 expression, and causes TRAIL-dependent apoptotic cell death. KDM4A inhibition also strongly sensitizes cells to TRAIL. C-4 alone potently inhibits tumor growth with marked induction of TRAIL and DR5 expression in the treated tumors and effectively sensitizes them to the newly developed TRAIL-inducer ONC201. Mechanistically, C-4 does not appear to act through the Akt-ERK-FOXO3a pathway. Instead, it switches histone modifying enzyme complexes at promoters of TRAIL and DR5 transcriptional activator CHOP gene by dissociating KDM4A and nuclear receptor corepressor (NCoR)-HDAC complex and inducing the recruitment of histone acetylase CBP. Thus, our results reveal KDM4A as a key epigenetic silencer of TRAIL and DR5 in tumors and establish inhibitors of KDM4A as a novel strategy for effectively sensitizing tumors to TRAIL pathway-based therapeutics.

Original languageEnglish
Pages (from-to)1886-1896
Number of pages11
JournalCell Death and Differentiation
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Epigenomics
Neoplasms
Death Domain Receptors
Therapeutics
TNF-Related Apoptosis-Inducing Ligand Receptors
Histone Acetyltransferases
Co-Repressor Proteins
MAP Kinase Signaling System
Gene Silencing
Histones
Chromatin
Lung Neoplasms
Prostatic Neoplasms
Breast
Cell Death
Clinical Trials
Antibodies
Enzymes
Growth
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. / Wang, Junjian; Wang, Haibin; Wang, Ling Yu; Cai, Demin; Duan, Zhijian; Zhang, Yanhong; Chen, Peng; Zou, June X.; Xu, Jianzhen; Chen, Xinbin; Kung, Hsing Jien; Chen, Hong Wu.

In: Cell Death and Differentiation, Vol. 23, No. 11, 01.11.2016, p. 1886-1896.

Research output: Contribution to journalArticle

Wang, J, Wang, H, Wang, LY, Cai, D, Duan, Z, Zhang, Y, Chen, P, Zou, JX, Xu, J, Chen, X, Kung, HJ & Chen, HW 2016, 'Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy', Cell Death and Differentiation, vol. 23, no. 11, pp. 1886-1896. https://doi.org/10.1038/cdd.2016.92
Wang, Junjian ; Wang, Haibin ; Wang, Ling Yu ; Cai, Demin ; Duan, Zhijian ; Zhang, Yanhong ; Chen, Peng ; Zou, June X. ; Xu, Jianzhen ; Chen, Xinbin ; Kung, Hsing Jien ; Chen, Hong Wu. / Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. In: Cell Death and Differentiation. 2016 ; Vol. 23, No. 11. pp. 1886-1896.
@article{7ab46f12ce5b4054a7a17a315365d0bf,
title = "Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy",
abstract = "Recombinant TRAIL and agonistic antibodies to death receptors (DRs) have been in clinical trial but displayed limited anti-cancer efficacy. Lack of functional DR expression in tumors is a major limiting factor. We report here that chromatin regulator KDM4A/JMJD2A, not KDM4B, has a pivotal role in silencing tumor cell expression of both TRAIL and its receptor DR5. In TRAIL-sensitive and -resistant cancer cells of lung, breast and prostate, KDM4A small-molecule inhibitor compound-4 (C-4) or gene silencing strongly induces TRAIL and DR5 expression, and causes TRAIL-dependent apoptotic cell death. KDM4A inhibition also strongly sensitizes cells to TRAIL. C-4 alone potently inhibits tumor growth with marked induction of TRAIL and DR5 expression in the treated tumors and effectively sensitizes them to the newly developed TRAIL-inducer ONC201. Mechanistically, C-4 does not appear to act through the Akt-ERK-FOXO3a pathway. Instead, it switches histone modifying enzyme complexes at promoters of TRAIL and DR5 transcriptional activator CHOP gene by dissociating KDM4A and nuclear receptor corepressor (NCoR)-HDAC complex and inducing the recruitment of histone acetylase CBP. Thus, our results reveal KDM4A as a key epigenetic silencer of TRAIL and DR5 in tumors and establish inhibitors of KDM4A as a novel strategy for effectively sensitizing tumors to TRAIL pathway-based therapeutics.",
author = "Junjian Wang and Haibin Wang and Wang, {Ling Yu} and Demin Cai and Zhijian Duan and Yanhong Zhang and Peng Chen and Zou, {June X.} and Jianzhen Xu and Xinbin Chen and Kung, {Hsing Jien} and Chen, {Hong Wu}",
year = "2016",
month = "11",
day = "1",
doi = "10.1038/cdd.2016.92",
language = "English",
volume = "23",
pages = "1886--1896",
journal = "Cell Death and Differentiation",
issn = "1350-9047",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy

AU - Wang, Junjian

AU - Wang, Haibin

AU - Wang, Ling Yu

AU - Cai, Demin

AU - Duan, Zhijian

AU - Zhang, Yanhong

AU - Chen, Peng

AU - Zou, June X.

AU - Xu, Jianzhen

AU - Chen, Xinbin

AU - Kung, Hsing Jien

AU - Chen, Hong Wu

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Recombinant TRAIL and agonistic antibodies to death receptors (DRs) have been in clinical trial but displayed limited anti-cancer efficacy. Lack of functional DR expression in tumors is a major limiting factor. We report here that chromatin regulator KDM4A/JMJD2A, not KDM4B, has a pivotal role in silencing tumor cell expression of both TRAIL and its receptor DR5. In TRAIL-sensitive and -resistant cancer cells of lung, breast and prostate, KDM4A small-molecule inhibitor compound-4 (C-4) or gene silencing strongly induces TRAIL and DR5 expression, and causes TRAIL-dependent apoptotic cell death. KDM4A inhibition also strongly sensitizes cells to TRAIL. C-4 alone potently inhibits tumor growth with marked induction of TRAIL and DR5 expression in the treated tumors and effectively sensitizes them to the newly developed TRAIL-inducer ONC201. Mechanistically, C-4 does not appear to act through the Akt-ERK-FOXO3a pathway. Instead, it switches histone modifying enzyme complexes at promoters of TRAIL and DR5 transcriptional activator CHOP gene by dissociating KDM4A and nuclear receptor corepressor (NCoR)-HDAC complex and inducing the recruitment of histone acetylase CBP. Thus, our results reveal KDM4A as a key epigenetic silencer of TRAIL and DR5 in tumors and establish inhibitors of KDM4A as a novel strategy for effectively sensitizing tumors to TRAIL pathway-based therapeutics.

AB - Recombinant TRAIL and agonistic antibodies to death receptors (DRs) have been in clinical trial but displayed limited anti-cancer efficacy. Lack of functional DR expression in tumors is a major limiting factor. We report here that chromatin regulator KDM4A/JMJD2A, not KDM4B, has a pivotal role in silencing tumor cell expression of both TRAIL and its receptor DR5. In TRAIL-sensitive and -resistant cancer cells of lung, breast and prostate, KDM4A small-molecule inhibitor compound-4 (C-4) or gene silencing strongly induces TRAIL and DR5 expression, and causes TRAIL-dependent apoptotic cell death. KDM4A inhibition also strongly sensitizes cells to TRAIL. C-4 alone potently inhibits tumor growth with marked induction of TRAIL and DR5 expression in the treated tumors and effectively sensitizes them to the newly developed TRAIL-inducer ONC201. Mechanistically, C-4 does not appear to act through the Akt-ERK-FOXO3a pathway. Instead, it switches histone modifying enzyme complexes at promoters of TRAIL and DR5 transcriptional activator CHOP gene by dissociating KDM4A and nuclear receptor corepressor (NCoR)-HDAC complex and inducing the recruitment of histone acetylase CBP. Thus, our results reveal KDM4A as a key epigenetic silencer of TRAIL and DR5 in tumors and establish inhibitors of KDM4A as a novel strategy for effectively sensitizing tumors to TRAIL pathway-based therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84986538313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986538313&partnerID=8YFLogxK

U2 - 10.1038/cdd.2016.92

DO - 10.1038/cdd.2016.92

M3 - Article

C2 - 27612013

AN - SCOPUS:84986538313

VL - 23

SP - 1886

EP - 1896

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

SN - 1350-9047

IS - 11

ER -